Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Board Appointment

4 Sep 2017 07:00

RNS Number : 6139P
Ideagen PLC
04 September 2017
 

4 September 2017

Ideagen plc

 

("Ideagen" or the "Company")

 

Board Appointment

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, is pleased to announce the appointment of Tony Rodriguez to its board of directors as a non-executive director with immediate effect.

Mr Rodriguez, aged 48, is an experienced technology entrepreneur and software developer. After an early career in a number of blue-chip technology companies, he founded Avellino Technologies Ltd in 1997, and personally led the development of its data profiling software product, now known as TS Discovery, before its acquisition in 2004 by Harte Hanks Trillium. Subsequently he founded X88 Software, since acquired by Experian in 2014, where he led, as CEO and CTO, the development of its data management product (now known as Experian Pandora), which was recognised as a visionary by Gartner.

Jonathan Wearing, Chairman, commented that:

"We are delighted that Tony has agreed to join the Board. He brings to Ideagen a wealth of experience in successfully developing and commercialising market-leading software, which will be extremely helpful as we continue to drive forward the growth of the business."

Further information, as required pursuant to Schedule 2(g) of the AIM Rules for Companies, are set out below.

Current directorships and/or partnerships:

Former directorships and/or partnerships (within the last five years):

X88 Limited

X88 Software Limited

Tony Rodriguez Limited

There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Enquiries:

Ideagen plc

Tel: 01629 699100

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews / James Thompson (Corporate Finance)

Stephen Norcross (Corporate Broking)

 

About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in GRC (Governance, Risk and Compliance) and Content and Clinical solutions with a primary focus on organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete information lifecycle solutions that enable organisations to reduce risk, meet their regulatory and compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 3,000 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUGUQGBUPMGPG
Date   Source Headline
10th Aug 201711:45 amRNSDirector Dealing
28th Jul 20174:19 pmRNSDirector Dealing
18th Jul 20177:00 amRNSFinal Results
12th Jun 20178:45 amRNSHolding(s) in Company
18th May 20173:19 pmRNSExercise of Options and Total Voting Rights
17th May 20177:00 amRNSPre-Close Trading Update
11th May 20172:21 pmRNSHolding(s) in Company
31st Mar 20171:10 pmRNSDirector/PDMR Shareholding
30th Mar 201711:48 amRNSHolding(s) in Company
30th Mar 20177:00 amRNSNew Aviation SaaS contracts worth £1.8m
28th Mar 20179:16 amRNSHolding(s) in Company
27th Mar 20176:05 pmRNSHolding(s) in Company
23rd Mar 201710:49 amRNSDirectors' Dealing & Total Voting Rights
23rd Mar 20177:00 amRNSAcquisition and Placing to raise £10m
1st Mar 201711:47 amRNSExercise of Options and Total Voting Rights
1st Mar 20177:00 amRNSHolding(s) in Company
24th Feb 20172:28 pmRNSExercise of Options and Total Voting Rights
24th Feb 201712:20 pmRNSHolding(s) in Company
21st Feb 20177:00 amRNSExercise of Options and Total Voting Rights
1st Feb 201711:44 amRNSHolding(s) in Company
26th Jan 20178:29 amRNSDividend Timetable
24th Jan 20177:01 amRNSDirectorate Changes
24th Jan 20177:00 amRNSInterim Results
9th Dec 20167:00 amRNSAcquisition of IPI Solutions Ltd
7th Dec 20162:14 pmRNSHolding(s) in Company
28th Nov 20164:55 pmRNSHolding(s) in Company
24th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 201611:37 amRNSHolding(s) in Company
7th Nov 20167:00 amRNSTrading Update
2nd Nov 20167:00 amRNSExercise of Options and Total Voting Rights
28th Oct 20161:26 pmRNSResult of AGM
13th Oct 20167:00 amRNSNew Contract Wins worth £1.2m
11th Oct 20167:00 amRNSExercise of Options and Total Voting Rights
6th Oct 20167:00 amRNSNotice of AGM
6th Sep 20167:00 amRNSAcquisition of Logen Ltd.
1st Sep 20167:00 amRNSExercise of Options and Total Voting Rights
12th Aug 20167:00 amRNSExercise of Options and Total Voting Rights
8th Aug 20167:00 amRNSAcquisition of Covalent Software Ltd
29th Jul 20167:00 amRNSExercise of Options and Total Voting Rights
19th Jul 20163:28 pmRNSDividend Timetable
19th Jul 20167:00 amRNSFinal Results
12th Jul 20167:00 amRNSNotice of Results
5th Jul 20167:00 amRNSHolding(s) in Company
29th Jun 20161:56 pmRNSHolding(s) in Company
18th May 20167:00 amRNSPre-Close Trading Update
5th May 20167:00 amRNSExercise of Options and Total Voting Rights
29th Apr 20167:00 amRNSNew contract wins in life science sector
29th Mar 20167:00 amRNSExercise of Options and Total Voting Rights
18th Mar 20167:00 amRNSRe £4.9m Contract and Trading Update
29th Jan 20168:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.